Kornimate/medical-research-clean huggingface dataset:
upper extremity rehabilitation with virtual reality in parkinson's disease patients

Conditions: Parkinson Disease; Virtual Reality; Neurological Rehabilitation; Upper Extremity Dysfunction

Summary: upper extremities are the first part of the body to be affected by parkinson's disease. although studies have shown that virtual reality-assisted rehabilitation methods are effective on gait and balance, studies on their use for upper extremity rehabilitation are limited. for this reason, the aim of the project is to examine whether virtual reality supported upper extremity position matching exercises, which will be specially prepared according to joint ranges of motion, will provide functional improvement in the upper extremities of individuals with parkinson's disease.

parkinson's disease (pd) is a neurodegenerative disorder characterized by motor disorders. difficulties in using the upper limbs caused by these motor impairments are common with the disease. upper limb motor impairments in pd include slowness of movement, difficulties in performing sequential tasks and limitations in upper limb function. studies show that the upper extremities are usually the most affected body region in the early stages of pd. despite this, the number of rehabilitation methods that can be used for upper extremity rehabilitation is limited. impairments in upper extremity motor function constitute a leading problem in the lives of individuals with pd by affecting their ability to perform activities of daily living. virtual reality applications stand out as an innovative approach in neurorehabilitation. previous studies have reported positive effects of virtual reality on gait function and balance in pd. however, the number of studies designed with virtual reality for the upper limb is limited. therefore, this project aims to fill the gap in the literature by examining the effectiveness of virtual reality-based rehabilitation in pd with a particular focus on upper extremity motor function and proprioception.

Eligibility criteria:
inclusion criteria: * accepting to participate in the research * being diagnosed with parkinson's disease by a neurologist * continuing anti-parkinsonian medication * hoehn-yahr (h-y) stage 3 and below * ability to walk independently * to have full range of motion in shoulder abduction and elbow extension movements exclusion criteria: * presence of additional neurological diseases other than parkinson's disease * scores below 21 on the montreal cognitive assessment scale * change in medication dosage in the last 1 month * severe visual impairment or complete hearing impairment in both ears * having a rheumatologic, musculoskeletal, etc. disease that may affect upper extremity functions * the occurrence of severe tremors or dyskinesias due to the end of the drug dose * failing the titmus butterfly test
study of ganetespib (sta-9090) + docetaxel in advanced non small cell lung cancer

Conditions: Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic

Summary: the purpose of this study is to determine whether combining ganetespib (sta-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

preliminary signals of clinical activity of ganetespib as a single agent have been observed in nsclc. a novel approach to treatment of nsclc is the combination of hsp90 inhibitors, such as ganetespib, and taxanes. such combinations have shown potential for synergy in preclinical and clinical evaluations with other hsp90 inhibitors. preclinical studies with ganetespib and taxanes have indicated that the combination of these drugs was more effective than either drug alone at inducing cell death, and an ongoing phase 1 study indicates that the combination is well tolerated and warrants systematic evaluation in a larger study.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of nsclc * stage iiib or iv nsclc * ecog performance status 0 or 1 * prior therapy defined as 1 prior systemic therapy for advanced disease * measurable disease * radiologic evidence of disease progression following most recent prior treatment. * adequate hematologic, hepatic, renal function exclusion criteria: * active or untreated cns metastases * active malignancies other than nsclc within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin * serious cardiac illness or medical conditions * pregnant or lactating women * uncontrolled intercurrent illness

Keywords: advanced non-small cell lung cancer nsclc lung cancer
expanded natural killer (nk) cells for multiple myeloma study

Conditions: Multiple Myeloma

Summary: high-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation (hsct) is considered standard treatment for patients with multiple myeloma. while autologous hsct may induce remission in patients resistant to standard chemotherapy, and has been shown to lead to long-lasting disease control in a subgroup of patients, the procedure is not curative. given enough time and in the absence of a competing cause of death, all patients eventually relapse after auto-hsct. the only potentially curative approach currently available in the treatment of multiple myeloma (mm) is stem cell trans-plantation from an allogeneic donor. allogeneic hsct eradicates residual myeloma cells through t-cell mediated graft-versus-tumor effects. allogeneic hsct is, however, associated with significant risk of graft-versus-host disease and its use is therefore limited to younger patients with high risk dis-ease. malignant plasma cells in multiple myeloma are also sensitive to natural killer cell lysis. natural killer cells do not cause graft-versus-host disease, which has led to interest in their therapeutic use in patients with multiple myeloma. we have previously shown that immunomagnetic separation of a highly pure nk cell product from a leukapheresis is possible and that these cells can be expanded up to 100-fold in a gmp-compatible setting. the current study aims to test the tolerability and feasibility of infusions of in vitro expanded haploidentical nk cells for patients after melphalan 200mg/m2 high dose chemotherapy and autologous hsct in 10 patients. if feasible, the data will provide a basis for further prospective studies.


Eligibility criteria:
inclusion criteria: * \> 18 years, with multiple myeloma and indication for an autologous hsct * available related haploidentical donor * written informed consent exclusion criteria: * patients scheduled for autologous/allogeneic tandem hsct
addressing emotional distress in dyads of persons with a young onset dementia (yod) and their care-partners

Conditions: Young Onset Dementia

Summary: the purpose of the present investigation is to test the efficacy of a virtual, brief (6 sessions) dyadic (patient and care-partner together) intervention to prevent chronic emotional distress in dyads where one person is diagnosed with young onset dementia (yod). through this study, we seek to address the unmet need of preventing chronic emotional distress in yod dyads through a feasible, acceptable and credible program, and ideally enhance resiliency and improve wellbeing and quality of life in both members of the dyad.


Eligibility criteria:
inclusion criteria: * between the ages of 18-65 at the time of enrollment \[both patient and care-partner\] * diagnosis of young-onset dementia (ftd, ppa, ad, pca, etc.) with symptom onset prior to age 65 \[patient\] * a designated care-partner willing and interested to participate \[both patient and care-partner\] * received yod diagnosis in the past 6 month \[patient\] * english fluency and literacy \[both patient and care-partner\] * cognitive ability to understand study and research protocol in order to consent to study participation \[both patient and care-partner\] * patient and/or caregiver exhibit emotional distress on screening (using hads d and/or hads a scores \> 7) exclusion criteria: * and additional, terminal diagnosis such as cancer * lack of access to internet and/or a device with a camera * current untreated or unstable severe mental health conditions like bipolar disorder, schizophrenia, or active substance use

Keywords: emotional distress dyadic intervention young onset dementia caregiving
assure study - arrhythmia single shock dft versus ulv: risk reduction evaluation with icd implantations

Conditions: Tachyarrhythmia

Summary: the assure study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (icd) is based on an implant test consisting of either 1) a single induction of ventricular fibrillation (vf) and subsequent demonstration conversion success at 14 j or 2) an upper limit of vulnerability (ulv) test at 14 j.


Eligibility criteria:
inclusion criteria: * patients who meet current indications for an icd including cardiac resynchronization therapy (crt) devices * patients who sign and date a patient informed consent form prior to the implant visit * patients who remain in the clinical care of the enrolling physician in approved centers * patients who receive only left-sided pectoral implantations with the icd lead placed in the right ventricular apex * patients who have a minimum r wave of at least 7 mv; or for icd replacement, patients who have a minimum chronic r wave of at least 5 mv exclusion criteria: * patients who are involved in non-invasive programming stimulation (nips) studies * patients who undergo lead repositioning * patients who are expected to receive a heart transplant during the duration of the study * patients who have or who are likely to receive a tricuspid valve prosthesis * patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study * patients who are younger than 18 years of age * patients who are pregnant or plan to become pregnant during the study * patients whose life expectancy is less than 12 months * patients who are mentally incompetent and cannot sign a patient informed consent form or comply with the study
reducing elevated heart rate in patients with severe sepsis by ivabradine

Conditions: Sepsis, Severe

Summary: rehsi is a prospective, multi-center, open label, randomized, controlled two arms, to evaluate the ability of ivabradine to reduce an elevated heart rate in septic shock patients. the primary end point is the reduction of heart rate within 24 hours. this trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed septic shock (despite adequate fluid resuscitation, were still requiring high-dose norepinephrine (ne) to maintain a mean arterial pressure (map) ≥65 mmhg , and had a tachycardia \>100 beats per minute (bpm). treatment period will last 4 days. all patients will be followed for up to six months.


Eligibility criteria:
inclusion criteria: 1. severe sepsis due to coronary and non-coronary etiology 2. severe sepsis diagnosed ≤ 24 h 3. sinus rhythm with heart rate ≥ 100bpm 4. written informed consent or identified or suspected positive will with respect to the trial treatment exclusion criteria: 1. patients who have not yet completed the 18th year of age 2. pregnancy, lactation 3. patients with a history of pre-existing chronic renal failure with a glomerular filtration rate \<30ml/min 4. severe hepatic insufficiency 5. sick sinus syndrome 6. sinu-atrial block 7. pacemaker-dependency 8.3rd degree av block 9.use of potent cytochrome p450 3a4 inhibitors such as antifungals of the azole -type (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), hiv protease inhibitors (nelfinavir, ritonavir) and nefazodone (see summary of product characteristics (spc))

Keywords: ivabradine sepsis heart rate
pd-l1 targeting molecular imaging of solid tumors

Conditions: Gastrointestinal Tumors

Summary: the objective of the study is to constrcut a noninvasive approach wl12 pet/ct to detect the pd-l1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-pd-1/l1 treatment.


Eligibility criteria:
inclusion criteria: * 1. aged \>18 years old; ecog 0 or 1; * 2. patients with gastrointestinal tumors; * 3. has at least one measurable target lesion according to response evaluation criteria in solid tumors (recist v1.1); * 4. life expectancy \>=12 weeks. exclusion criteria: * 1. significant hepatic or renal dysfunction; * 2. is pregnant or ready to pregnant; * 3. cannot keep their states for half an hour; * 4. refusal to join the clinical study; * 5. suffering from claustrophobia or other mental diseases; * 6. any other situation that researchers think it is not suitable to participate in the experiment.
a study of tas2940 in participants with locally advanced or metastatic solid tumor cancer

Conditions: Solid Tumor; Glioblastoma; Non-small Cell Lung Cancer; Breast Cancer

Summary: this is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of tas2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.

tas2940 is a small molecule inhibitor of erbb family proteins her2 and egfr. it has not been evaluated in human subjects yet. the study will be conducted in 2 parts, dose escalation and dose expansion. the dose escalation part will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of tas2940 administered orally. the dose expansion part will assess preliminary anti-tumor activity in select solid tumors characterized by her2 or egfr aberrations.

Eligibility criteria:
inclusion criteria: * have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted * have adequate organ function * ecog ps 0-1 dose escalation: * have measurable or non- measurable disease per recist criteria v1.1 or rano * any solid tumor with egfr and / or her2 aberration dose expansion: * have measurable disease per recist criteria v1.1 for solid tumor (excluding primary brain tumor) or rano (for glioblastoma) * cohort a: non-small cell lung cancer (nsclc) * cohort b: her2 positive breast cancer * cohort c: recurrent or refractory glioblastoma * cohort d: other solid tumors with egfr or her2 aberrations exclusion criteria: * non-stable brain metastases * have significant cardiovascular disorder * have not recovered from prior cancer treatment * a serious illness or medical condition
evaluation of tumor response to ipilimumab in the treatment of melanoma with brain metastases

Conditions: Melanoma

Summary: to assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.


Eligibility criteria:
key inclusion criteria * histologically confirmed malignant melanoma * at least 1 measurable index brain metastasis \>0.5 cm and no larger than 3 cm in diameter that had not been previously irradiated, and/or 2 measurable lesions \>0.3 cm visible on contrast magnetic resonance * index brain lesion must have resolved consequences of prior therapy that could have confounded attribution of tumor response including edema and hemorrhage * participants in ipilimumab monotherapy arm (including the first 21 who were enrolled in stage 1) were to be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy in the 10 days prior to beginning ipilimumab therapy * eastern cooperative oncology group performance status of 0 or 1 * required values for initial laboratory tests: * white blood cell count ≥2000/μl * absolute neutrophil count ≥1000/μl * platelets ≥100\*10\^3/μl * hemoglobin level ≥9 g/dl (may have been transfused) * aspartate aminotransferase/alanine aminotransferase (ast/alt) level ≤2.5\*uln for participants without liver metastasis * ast/alt level ≤5\*uln for those with liver metastasis * bilirubin level ≤2\*uln (except participants with gilbert's syndrome, who must have had a total bilirubin level less than 3.0 mg/dl) * age 16 years and older * males and females * women of childbearing potential (wobp) must be using an adequate method of contraception to avoid pregnancy throughout the study (and for up to 26 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized. wocbp include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. key exclusion criteria * history of carcinomatous meningitis, with prior stereotactic or highly conformal radiotherapy and/or whole brain irradiation within 14 days before the first dose of ipilimumab, and documented history of autoimmune disease * prior stereotactic or highly conformal radiotherapy and/or whole brain irradiation within 14 days prior to start of ipilimumab dosing for this study. note the stereotactic radiotherapy field must not have included the brain index lesion or the lesion must have been detected and confirmed to be active and progressing after receiving whole brain irradiation.
inspiratory flow and volumes in bronchiectatics

Conditions: Bronchiectasis

Summary: adequate administration of drugs via dry powder inhalers is dependent on adequate inspiratory flow rates and volumes. these vary according to the device being used and its resistance. the dry powder inhaler device under investigation is a device approved by the therapeutic goods administration (artg no. 196255) for use with dry powder mannitol. dry powder mannitol is currently being investigated as a treatment for bronchiectasis. we wish to measure the inspiratory flow characteristics of both the low and high resistance devices amongst a group of subjects with bronchiectasis. we propose that the majority of subjects investigated with varying lung function will achieve adequate flow during a controlled inspiration.


Eligibility criteria:
inclusion criteria: * non-cf bronchiectasis * aged 18-80 inclusive * fev1 greater or equal to 50% predicted and greater or equal to 1l exclusion criteria: * uncontrolled asthma * cf bronchiectasis * have any condition for which spirometry measurement would be contraindicated

Keywords: measure inspiratory spirometry with dry powder inhaler device in series with the spirometer
indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of icam-1 in acute kidney injury

Conditions: Renal Function Disorder

Summary: indoxyl sulfate (is) is an anionic uremic toxin that is accumulated in the serum of patients with uremia. in previous study, the investigators successfully induced aki animal model. is enhanced intercellular adhesion molecule-1 (icam-1) expression in il-1β-treated human umbilical vein endothelial cells (huvecs) that this may play a critical role in the progression of aki. however, the molecular mechanisms of icam-1 expression in is-treated il-1β-treated huvecs need to be elucidated. huvecs incubated with 0.2 or 1 mm is for 24 h did not cause cytotoxicity. the il-1β-induced icam-1 expression in huvecs was significantly enhanced by is pretreatment. furthermore, the regulation of adhesion molecule expression involves a complex array of intracellular signaling pathways including mitogen-activated protein kinase (mapks), reactive oxygen species (ros) and transcriptional factors. a better understanding of this might provide important insights into the prevention of aki.

over the past decade, acute kidney injury (aki) has acquired much attention because of their potentially devastating problems in clinical medicine. when kidneys lost their filtering function, a lot of dangerous metabolites were accumulated in the body, including urea, nitrogenous waste products and uremic toxins. indoxyl sulfate (is) is an anionic uremic toxin that is accumulated in the serum of patients with uremia. in previous study, the investigators successfully induced aki animal model. is enhanced intercellular adhesion molecule-1 (icam-1) expression in il-1β-treated human umbilical vein endothelial cells (huvecs) that this may play a critical role in the progression of aki. however, the molecular mechanisms of icam-1 expression in is-treated il-1β-treated huvecs need to be elucidated. huvecs incubated with 0.2 or 1 mm is for 24 h did not cause cytotoxicity. the il-1β-induced icam-1 expression in huvecs was significantly enhanced by is pretreatment. furthermore, the regulation of adhesion molecule expression involves a complex array of intracellular signaling pathways including mitogen-activated protein kinase (mapks), reactive oxygen species (ros) and transcriptional factors. a better understanding of this might provide important insights into the prevention of aki.

Eligibility criteria:
inclusion criteria: * icu patients exclusion criteria: * less than 20 years old

Keywords: acute kidney injury
assessment of a carvacrol-loaded absorbable gelatin sponge used as a palatal dressing following free gingival graft harvesting: a randomized clinical study

Conditions: Palatal Wound

Summary: to evaluate the effect of carvacrol loaded to absorbable gelatin sponge as a palatal bandage on the palatal donor site in post-operative pain reduction after free gingival graft harvesting


Eligibility criteria:
inclusion criteria: 1 - patients with mucogingival defects scheduled for free gingival graft. 2- medically free patients 3- palate with sufficient connective tissue to accommodate soft tissue defects. 4- good oral hygiene exclusion criteria: 1 - smokers 2- pregnancy 3- medically compromised patients 4- severe gag reflex 5- patients allergic to the used agent 6- occlusal trauma at the site of graft
association between non-alcoholic fatty liver disease (nafld) and coronary artery calcification

Conditions: Coronary Artery Calcification

Summary: coronary artery disease are 8 times more prevalent in patients with nafld then the general population and are being considered the most common cause of death. cardiac ct is a reliable non invasive method in demonstrating coronary plaques. however the association between coronary artery calcium score (cac) and nafld remains controversial

coronary artery disease are 8 times more prevalent in patients with nafld that the general population and are being considered the most common cause of death. cardiac ct is a reliable non invasive method in demonstrating coronary plaques. however the association between coronary artery calcium score (cac) and nafld remains controversial. aim: the aim is to evaluate the association between cac score ( ct) and nafld (ct). the working hypothesis is that beside the traditional risk factors including age, diabetes, nafld is also associated with moderate to high risk of cad.

Eligibility criteria:
inclusion criteria: * patients who will undergo cardiac ct for patients with low to intermediate risk for cad exclusion criteria: * patients with pci or cabg will be excluded

Keywords: nafld calcium score liver fat visceral fat excessive visceral fat excessive liver fat accumulation biomarkers of insulin resistance (homa), inflammation (crp) and (mda-paraoxonase)